FTC, GeneLink and Subsidiary Reach Deal to Settle Charges of False Advertising | GenomeWeb

NEW YORK (GenomeWeb News) – The US Federal Trade Commission announced on Tuesday it has reached an agreement with GeneLink and its former subsidiary foru International to settle charges of deceptive advertising claims made by the companies about their personalized nutritional supplements.

The settlement, which is not yet final, would also resolve allegations that GeneLink and foru engaged in "lax information security practices," the FTC said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.